166. Pseudoxanthoma elasticum
11 clinical trials,   23 drugs   (DrugBank: 6 drugs),   5 drug target genes,   26 drug target pathways

Searched query = "Pseudoxanthoma elasticum", "PXE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04660461
(ClinicalTrials.gov)
February 4, 20203/12/2020Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Drug: Lansoprazole 30mg;Drug: PlaceboFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludNULLRecruiting18 YearsN/AAll20Phase 4Spain
2EUCTR2016-004021-16-ES
(EUCTR)
31/10/201810/03/2017Response to oral lansoprazole in patients with Pseudoxanthoma ElasticumResponse to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) - FIM-PXE-2016-01 Grönblad-Stranberg disease (Pseudoxanthoma Elasticum)
MedDRA version: 19.1;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Lansoprazole
INN or Proposed INN: Lansolprazole
Other descriptive name: LANSOPRAZOLE
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2Spain